drugset / Trial / NCT01363713

A Long-term Study of DE-114 Ophthalmic Solution in Patients With Allergic Conjunctivitis

NCT01363713

Phase 3 Completed 130 enrolled Santen Pharmaceutical Co., Ltd.

Summary

Safety and efficacy of DE-114 ophthalmic solution will be evaluated in patients with allergic conjunctivitis, in an open-label, multicenter study.

Timeline

Start
Primary completion
2012-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Epinastine Small molecule

Indications